These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 10669157

  • 1. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.
    Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E, Kruitwagen CL, Sixma JJ, van den Berg HM.
    Thromb Haemost; 2000 Jan; 83(1):65-9. PubMed ID: 10669157
    [Abstract] [Full Text] [Related]

  • 2. Familial clustering of factor VIII and von Willebrand factor levels.
    Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen HC, Eikenboom JC, Bertina RM, Rosendaal FR.
    Thromb Haemost; 1998 Feb; 79(2):323-7. PubMed ID: 9493584
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Factor VIII half-life and intensity of treatment in hemophilic patients.
    Vicente V.
    Haematologica; 2005 Apr; 90(4):437. PubMed ID: 15820932
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R.
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease.
    Böhm M, Täschner S, Kretzschmar E, Gerlach R, Favaloro EJ, Scharrer I.
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):39-45. PubMed ID: 16607078
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.
    Fijnvandraat K, Berntorp E, ten Cate JW, Johnsson H, Peters M, Savidge G, Tengborn L, Spira J, Stahl C.
    Thromb Haemost; 1997 Feb; 77(2):298-302. PubMed ID: 9157585
    [Abstract] [Full Text] [Related]

  • 11. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
    Zourikian N, Merlen C, Bonnefoy A, St-Louis J, Rivard GE.
    Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
    [Abstract] [Full Text] [Related]

  • 12. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.
    Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L, Favaloro JW.
    Am J Clin Pathol; 2005 Dec; 124(6):910-7. PubMed ID: 16416741
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques.
    Bennett B, Ratnoff OD.
    J Clin Invest; 1972 Oct; 51(10):2593-6. PubMed ID: 4626847
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ.
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [Abstract] [Full Text] [Related]

  • 16. Carrier detection in hemophilia A: ABO blood group, multiple measurements, and application of logistic discrimination.
    Percy ME, Rusk AC, Garvey MB, Freedman JJ, Teitel JM, Blake P, Carter C, Andrew M, Johnson M, Inwood M.
    Am J Med Genet; 1988 Dec; 31(4):871-9. PubMed ID: 3149148
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients.
    Fischer K, Pendu R, van Schooten CJ, van Dijk K, Denis CV, van den Berg HM, Lenting PJ.
    PLoS One; 2009 Aug 25; 4(8):e6745. PubMed ID: 19707594
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of ABO blood group on haemostatic parameters in severe haemophilia A patients performing acute moderate-intensity exercise.
    Merlen C, Zourikian N, Bonnefoy A, Dubé E, Thibeault C, St-Louis J, Rivard GE.
    Blood Coagul Fibrinolysis; 2018 Nov 25; 29(7):626-635. PubMed ID: 30036280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.